JAKi monotherapy is an effective and generally well-tolerated treatment strategy for patients with RA, showing superior efficacy to conventional DMARDs and placebo and comparable efficacy to TNF inhibitors and JAKi combination therapy. This evidence concerns the gene TNF and rheumatoid arthritis.